Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 30, 2006 Stephen D. Simpson	A Bard's Tale The advanced medical technology company's stock already reflects new products' potential. Still, life in the med-tech sector could get more interesting in the coming quarters. Investors, take note.
The Motley Fool April 20, 2005 Stephen D. Simpson	A Healing Look at Bard Medical device maker C.R. Bard shows that boring can be beautiful so long as boring pays the bills. Investors, take note.
The Motley Fool August 18, 2005 Stephen D. Simpson	Medtronic Keeps the Beat Strong growth in the ICD and spinal businesses keep Medtronic running. The stock is trading more or less at par to the market with respect to its P/E-to-growth ratio. Investors must decide for themselves whether that's a fair price to pay.
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool January 26, 2007 Matthew Crews	Bard's Costly Quarter? The medical device company suffered from multiple one-time charges. Investors who've seen the cup as half full have fared much better here than with many other med-tech companies.
The Motley Fool January 30, 2006 Stephen D. Simpson	Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool May 24, 2006 Stephen D. Simpson	Measuring Up Medtronic Everyone loves the med-tech firm. That makes it a dangerous investment.
The Motley Fool February 24, 2010 Brian Orelli	Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products.
The Motley Fool February 17, 2006 Stephen D. Simpson	AtriCure Sends Investors' Hearts Aflutter AtriCure addresses a real market, but faces a typically rocky road. But executing on a big opportunity can mean ample rewards for patient investors.
The Motley Fool August 25, 2009 Brian Orelli	Medtronic Takes the Road Less Traveled It looks like this medical devices company is healthy again.
The Motley Fool February 22, 2006 Stephen D. Simpson	Medtronic's Minor Miss Sluggish sales in several market categories might spook investors.
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
The Motley Fool January 6, 2005 Stephen D. Simpson	Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past.
The Motley Fool November 18, 2004 W.D. Crotty	Medtronic Down, Not Out Internal defibrillator maker's earnings growth rate is slowing down, but its future looks healthy.
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool August 4, 2006 Stephen D. Simpson	Medtronic's Shock to the System Its guidance cuts rattled the med-tech industry, but long-term trends remain positive. While the going may be tougher now in the ICD space, it's still an attractive long-term opportunity, and investors may want to start looking around for bargains.
The Motley Fool February 17, 2009 Brian Orelli	Investors Heart Medtronic The leaner company is more lovable.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool November 24, 2009 Brian Orelli	52-Week Highs! What's Going On? Even with its recent leap, this stock may belong in your portfolio. Medtronic raised earnings guidance today after a fairly strong quarter, and the stock is hitting new 52-week highs.
The Motley Fool August 24, 2011 Brian Orelli	Growth, but Not Great Growth Medtronic's growth comes with lower margins.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool April 19, 2007 Billy Fisher	A Saintly Quarter Shares of St. Jude Medical rise after the company announces a big quarter.
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
The Motley Fool February 12, 2004 Jeff Hwang	Rockin' Medtronic The world's premier medical device maker keeps on growing.
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
The Motley Fool August 20, 2008 Brian Orelli	Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool August 23, 2006 Stephen D. Simpson	Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution.
The Motley Fool July 27, 2006 Stephen D. Simpson	Growth Ingrates Dump Intuitive Surgical Despite today's sell-off, Intuitive Surgical remains a red-hot grower in the med-tech space.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool August 24, 2010 Brian Orelli	Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm.
The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool April 21, 2009 Brian Orelli	Boston Scientific Rebuilds Whether the company is a value or a value trap depends on how well the rebuilding goes this year.
The Motley Fool February 27, 2006 Stephen D. Simpson	A Foxy Idea? Medical device maker Foxhollow is in an attractive niche, but management turnover is a reason for investors to worry.
The Motley Fool August 18, 2008 Brian Orelli	Foolish Forecast: Taking Medtronic to Heart In advance of earnings analysts expect Medtronic, with another medical device approval, to boost revenues 17%.
The Motley Fool November 21, 2006 Ryan Fuhrmann	Shocking Results at Medtronic Favorable earnings boost shares of this medical equipment maker -- but are they too high already?
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool July 6, 2007 Billy Fisher	Medtronic: For the Broken-Hearted Promising clinical trial could bring a new Medtronic stent to market. Investors, take note.
The Motley Fool March 30, 2006 Stephen D. Simpson	Arrow International's Dead Release Results at this medical device manufacturer look better than they really are. Investors, take note.
The Motley Fool October 19, 2011 Brian Orelli	This High-Tech Company Still Has the Touch Intuitive Surgical beats analysts' expectations. Again.
The Motley Fool May 26, 2004 Alyce Lomax	Medtronic Takes Heart After the stock drops on data, what does the company have to say?
The Motley Fool February 20, 2008 Brian Orelli	Medtronic Looks Ahead After a rough second half of last year, Medtronic is leaving its problems behind, and optimistically focusing on the future.
The Motley Fool June 30, 2006 Stephen D. Simpson	Arrow's Erratic Flight Progress for the med-tech is still slow in coming, though market rewards have come faster. Investors, take note.
The Motley Fool August 21, 2006 Stephen D. Simpson	Kensey Nash Losing the Benefit of the Doubt Med-tech investors won't wait indefinitely for growth. Investors can find better values in this sector if they're willing to roll up their sleeves for some due diligence.